Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer Nov 27, 2023
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update Nov 13, 2023
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy Nov 2, 2023
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director Nov 1, 2023
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents Sep 27, 2023
